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Abstract 
Background. GNPAT p.D519G positivity is significantly increased in HFE p.C282Y 
homozygotes with markedly increased iron stores. We sought to determine associations of 
p.D519G and iron-related variables with iron stores in p.C282Y homozygotes. Methods. We 
defined markedly increased iron stores as serum ferritin >2247 pmol/L (>1000 µg/L) and either 
hepatic iron >236 µmol/g dry weight or iron >10 g by induction phlebotomy (men and women). 
We defined normal or mildly elevated iron stores as serum ferritin <674.1 pmol/L (<300 µg/L) 
and either age ≥40 y with iron ≤2.5 g iron by induction phlebotomy or age ≥50 y with ≤3.0 g iron 
by induction phlebotomy (men only). We compared participant subgroups using univariable 
methods. Using multivariable logistic regression, we evaluated associations of markedly 
increased iron stores with these variables: age; iron supplement use (dichotomous); whole blood 
units donated; erythrocyte units received as transfusion; daily alcohol consumption, g; and 
p.D519G positivity (heterozygosity or homozygosity). Results. The mean age of 56 participants 
(94.6% men) was 55 ± 10 (SD) y; 41 had markedly increased iron stores. Prevalences of 
swollen/tender 2nd/3rd metacarpophalangeal joints and elevated aspartate or alanine 
aminotransferase were significantly greater in participants with markedly increased iron stores. 
Only participants with markedly increased iron stores had cirrhosis. In multivariable analyses, 
p.D519G positivity was the only exposure variable significantly associated with markedly 
increased iron stores (odds ratio 9.9, 95% CI [1.6, 60.3], p = 0.0126). Conclusions. GNPAT 
p.D519G is strongly associated with markedly increased iron stores in p.C282Y homozygotes 
after correction for age, iron-related variables, and alcohol consumption. 
 
Key words for indexing: hemochromatosis; iron overload; rs11558492; rs1800562 
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Abbreviations
1
  
                                                 
1
 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; SD, standard deviation; SF, 
serum ferritin. 
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1.0 Introduction 
HFE hemochromatosis is an autosomal recessive condition attributed to homozygosity for the 
p.C282Y mutation (rs1800562) of the HFE gene (chromosome 6p21.3) [1,2]. p.C282Y 
homozygosity occurs in 0.3-0.6% of persons of European descent and accounts for ~90% of 
hemochromatosis iron phenotypes in whites [2,3]. Decreased hepcidin expression and 
consequent excessive iron absorption cause iron overload in p.C282Y homozygotes [4], although 
clinical penetrance of iron overload in many p.C282Y homozygotes is mild [5,6]. Among 
persons diagnosed to have hemochromatosis and p.C282Y homozygosity in non-screening 
venues, the prevalence of iron overload and associated complications such as diabetes, other 
endocrinopathy, cirrhosis, primary liver cancer, and cardiomyopathy is relatively high [3]. In 
contrast, the results of population screening studies in whites in European and derivative 
countries reveal that the proportions of p.C282Y homozygotes who have or develop iron 
overload and related complications varies but is relatively low [5-8]. Thus, p.C282Y 
homozygosity is necessary but not sufficient to cause hemochromatosis iron phenotypes [9]. 
 
Gender, age, diet, and blood loss account in part for iron phenotype variability in persons with 
hemochromatosis [10-12]. Modifier mutations in non-HFE iron-related genes described to date 
explain iron phenotype variability in a small proportion of p.C282Y homozygotes [3,13]. 
Accordingly, it is assumed that other acquired or environmental factors and non-HFE 
polymorphisms of unreported or unconfirmed effect on iron absorption or iron stores account for 
much of the remaining unexplained iron phenotype variability among p.C282Y homozygotes 
[14].  
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GNPAT (chromosome 1q42.2) encodes the peroxisomal enzyme glyceronephosphate O-
acyltransferase [15]. The GNPAT polymorphism p.D519G (rs11558492) is a candidate modifier 
of iron phenotypes in p.C282Y homozygotes [16,17]. In an initial p.D519G report, we described 
35 men with p.C282Y homozygosity who did not report moderate or heavy daily alcohol 
consumption [16]. Positivity for p.D519G was significantly greater in the 22 men with markedly 
increased iron stores than in the 13 other men with normal or mildly elevated iron stores [16]. 
These results suggested that p.D519G modifies iron phenotypes in men with p.C282Y 
homozygosity without a history of moderate or heavy daily alcohol consumption either by 
enhancing iron absorption or because p.D519G is linked to a putative iron absorption promoter 
on chromosome 1q. 
 
To learn more, we evaluated the significance of GNPAT p.D519G as a putative modifier of iron 
phenotypes in 56 participants with p.C282Y homozygosity who were evaluated with exome 
sequencing. The present cohort (n = 56) included the original 35 men with markedly increased 
iron stores [16], 12 other men (11 of whom had markedly increased iron stores) who were 
excluded from our initial report because they reported moderate or heavy daily alcohol 
consumption [16], and 9 additional p.C282Y homozygotes (6 men, 3 women) whose exome 
sequencing had not been performed at the time of our initial report [16]. Of the 9 additional 
subjects, 8 had markedly increased iron stores (5 of the 6 men and all 3 women). We applied 
univariable statistical techniques to compare general observations in the 41 participants with 
markedly increased iron stores to those of the 15 other participants who had normal or mildly 
elevated iron stores. Using multivariable statistical techniques, we determined the significance of 
available variables, including positivity for p.D519G, which could contribute to the development 
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of markedly increased iron stores. We discuss the present results in the context of other reports 
of p.D519G and iron phenotypes in persons with p.C282Y homozygosity and other HFE 
genotypes. 
 
2.0 Methods 
2.1. Study performance. This study was performed in accordance with the Declaration of 
Helsinki. Approval was obtained from appropriate review boards at: University of California, 
Irvine; University of Western Ontario; QIMR Berghofer Medical Research Institute; Rochester 
General Health System; the Cancer Council Victoria; and Department of Veterans Affairs Long 
Beach Healthcare System. Written informed consent was obtained from all participants. 
Consortium study sites identified p.C282Y homozygotes in clinical practice settings associated 
with the investigators or by population screening through the Hemochromatosis and Iron 
Overload Screening (HEIRS) Study and a study of the Prevalence of Iron Overload and 
Frequency of the Hemochromatosis Gene conducted at the Department of Veterans Affairs Long 
Beach Healthcare System.  
  
2.2. Clinical and laboratory data collection. Information on demographics, blood donation, 
alcohol consumption, clinical observations, biochemical tests, and interpretation of liver biopsy 
specimens was obtained from medical records of participants identified through clinical practices 
and from the National Institutes of Health BioLincc biorepository for HEIRS Study participants 
[16]. Observations recorded at diagnosis of hemochromatosis included: age; sex; diabetes 
diagnoses; use of iron supplements; lifetime units of whole blood donation; lifetime units of 
erythrocytes received as transfusion; estimated daily alcohol consumption, g; body mass index; 
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swollen/tender 2nd/3rd metacarpophalangeal joints; serum levels of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST); and biopsy-proven cirrhosis. Elevated ALT and 
AST was defined as >0.67 µkat/L (>40 IU/L) for both. 
 
2.3. Exome sequencing. Quality control of sample DNA, exome capture and sequencing, and 
performance of sequence kernel association tests were performed at the University of 
Washington (Seattle, WA) as described in detail elsewhere [18].  
 
2.4. Participant selection. Inclusion criteria included: 1) p.C282Y homozygosity confirmed at 
exome sequencing; 2) participant was unrelated to other participants; 3) participant did not 
withdraw consent; and 4) participant did not refuse blood storage. Participants with markedly 
increased iron stores included men and women. By design, all participants with normal or mildly 
elevated iron stores were men, in order to avoid possible confounding effects of unquantifiable 
iron losses in women [16]. The participant selection schema is displayed in Fig. 1. 
 
2.5. Classification of iron phenotypes. Induction phlebotomy was defined as the amount of iron 
removed to achieve serum ferritin (SF) <112.4 pmol/L (<50 µg/L) [19]. Criteria for markedly 
increased iron stores were: SF >2247 pmol/L (>1000 µg/L) at diagnosis and either hepatic iron 
>236 µmol/g dry weight or iron >10 g by induction phlebotomy [20]. Criteria for normal or 
mildly elevated iron stores were: SF <674.1 pmol/L (<300 µg/L) or either age ≥40 y with iron 
≤2.5 g iron by induction phlebotomy or age ≥50 y with ≤3.0 g iron by induction phlebotomy 
[16].  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
revision of BCMD_2016_135 - 9 
  
 
2.6. Statistics 
We used observations for 56 participants in the present analyses. For one participant who 
reported having received erythrocyte transfusions of unknown number, we imputed a value of 
one unit of erythrocyte transfusion. Descriptive data are displayed as enumerations, percent (n), 
mean ± 1 standard deviation (SD), or odds ratios with 95% confidence limits obtained by 
inverting the Wald Test of the null hypothesis. To compare characteristics of those with 
markedly increased iron stores to those of participants with normal or mildly elevated iron stores 
we used Fisher's exact test and the Wilcoxon Rank-Sum test, as appropriate, and also applied 
univariable logistic regression models. We used multivariable logistic regression to estimate the 
magnitude of the association between markedly increased iron stores (dependent variable) and 
exposure variables that could influence iron phenotypes: age at diagnosis; use of iron 
supplements (dichotomous); units of whole blood donation; units of erythrocytes received as 
transfusion; estimated daily alcohol consumption, g; and positivity for GNPAT p.D519G 
(heterozygosity or homozygosity). We used SAS® v.9.4 (Statistical Analysis System, Cary, 
NC). 
 
3.0 Results 
3.1. General characteristics of participants. There were 56 participants (94.6% men); 55 
participants were white and the other one was African American. Mean age at hemochromatosis 
diagnosis was 55 ± 10 (SD) y. Forty-one participants (73.2%) were classified as having markedly 
increased iron stores. Seven participants (12.5%) were diagnosed to have diabetes. Use of iron 
supplements was reported by 12 participants (21.4%). Mean units of blood donation was 4 ± 9 
(range 0 – 50). Six participants (10.7%) reported that they had received erythrocyte transfusion.  
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Mean estimated daily alcohol consumption was 8 ± 15 g (range 0 – 75). Mean body mass index 
was 28.0 ± 5.2 kg/m
2
 (range 18.5 – 47.2). Swelling and/or tenderness of the 2nd/3rd 
metacarpophalangeal joints was reported in 23 participants (41.8%). Elevated ALT and AST 
levels at diagnosis were observed in 27 participants (51.9%) and 23 participants (41.8%), 
respectively. GNPAT p.D519G was detected in 26 participants (3 homozygotes, 23 
heterozygotes). One woman was a GNPAT p.D519G heterozygote and the other two women 
were negative for p.D519G. 
 
3.2. Participants with and without markedly increased iron stores. SF values in the two iron 
phenotype groups are displayed in Table 1. Comparisons of general characteristics between the 
two phenotype groups are displayed in Table 2. Prevalences of swollen/tender 2nd/3rd 
metacarpophalangeal joints, elevated ALT, and elevated AST were greater in participants with 
markedly increased iron stores (Table 2). Cirrhosis was diagnosed in 40.5% of 37 participants 
with markedly increased iron stores who underwent liver biopsy. Two participants with normal 
or mildly elevated iron stores who underwent liver biopsy did not have cirrhosis. Positivity for 
GNPAT p.D519G was greater in participants with markedly increased iron stores (Table 2). 
Twelve participants were excluded from the original study because they reported 
moderate/heavy alcohol consumption. Eleven had markedly increased iron stores and five of the 
eleven had p.D519G (3 heterozygotes, 2 homozygotes). The one patient without markedly 
increased iron stores was a p.D519G heterozygote. 
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3.3. Logistic regression on markedly increased iron stores. We evaluated these variables as 
possible contributors to markedly increased iron stores: age at diagnosis; use of iron 
supplements; whole blood units donated; units of erythrocytes received as transfusion; estimated 
daily alcohol consumption, g; and GNPAT p.D519G positivity (heterozygosity or 
homozygosity). The odds of participants with p.D519G positivity having markedly increased 
iron stores were 9.2 times higher (95% CI [1.8, 46.1]) than those of participants without 
p.D519G (Table 3). In a multivariable model, p.D519G positivity was significantly associated 
with markedly increased iron stores (odds ratio 9.9, 95% CI [1.6, 60.3], p = 0.0126). There was 
no significant association of other exposure variables with markedly increased iron stores. The 
area under the curve for the multivariable logistic regression model was 0.82. 
 
4.0 Discussion 
GNPAT p.D519G positivity (or a putative linked allele on chromosome 1q) could account for 
increased iron absorption in p.C282Y homozygotes with markedly increased iron stores. The 
present results confirm and extend observations in an initial phase of this study from univariable 
analyses of p.D519G allele frequency in smaller subsets of men classified by iron stores as 
defined herein [16]. The present findings are also consistent with observations that p.D519G 
positivity detected by SNP analysis was significantly associated with increased iron stores (>5 g 
mobilized within the first year of phlebotomy therapy) in univariable and multiple regression 
models of observations in p.C282Y homozygotes in southern France [17]. The allele frequency 
of GNPAT p.D519G (rs11558492) was also significantly greater in 77 unrelated French men 
with p.C282Y/p.H63D and severe iron phenotypes than in two European population control 
cohorts [21]. 
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GNPAT p.D519G positivity detected by SNP analysis was not significantly associated with 
increased iron stores represented by SF or quantities of iron removed by phlebotomy to achieve 
iron depletion in a large cohort of unselected p.C282Y homozygotes in northern France [22] and 
in 26 Canadian p.C282Y homozygotes [23] and was not associated with SF ≥2247 pmol/L 
(≥1000 μg/L) at diagnosis in Irish or Canadian p.C282Y homozygotes [23,24]. Analyses of 
observations in subgroups of men in two reports also yielded negative results [22,24]. In one 
report, SF 2247 pmol/L (>1000 µg/L) at diagnosis was the only definition of increased iron 
stores [24], unlike the more stringent definitions of markedly increased and normal or mildly 
elevated iron stores used in our initial-phase study [16], in a confirmatory investigation [17], and 
in the present study. SF is a surrogate measure of storage iron and diverse non-iron conditions 
[25]. Comparison of SF levels at diagnosis with quantities of iron removed by phlebotomy to 
achieve iron depletion in 54 p.C282Y homozygotes revealed that “the SF level does provide 
some information regarding total iron burden but even in the case of C282Y homozygotes, the 
correlation is not very strong” [26].  
 
The prevalence of swollen/tender metacarpophalangeal joints, a proxy for hemochromatosis 
hand arthropathy [3], was significantly greater in the present participants with markedly 
increased iron stores. This is consistent with a report that the prevalence of hand arthropathy is 
greater in p.C282Y homozygotes with SF >2247 pmol/L (>1000 µg/L) [27]. The proportion of 
participants with markedly increased iron stores who had elevated AST was significantly higher 
than that of participants with normal or mildly elevated iron stores. Elevated AST in patients 
with hemochromatosis and iron overload is generally interpreted to be a consequence of hepatic 
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injury, especially cirrhosis [28,29]. Cirrhosis was diagnosed in 41% of the 37 present participants 
with markedly increased iron stores who underwent liver biopsy, consistent with the association 
of cirrhosis and markedly elevated hepatic iron concentrations in other white adults with 
hemochromatosis who did not have alcoholism [30].  
 
Use of iron supplements was reported by more than 20% of the present participants, consistent 
with a survey of a large number of hemochromatosis patients [31]. Whether ingestion of 
supplemental inorganic iron increases iron overload severity in typical p.C282Y homozygotes is 
controversial. The present analyses did not detect a significant association of reports of 
supplemental iron use with markedly increased iron stores. In 213 screening p.C282Y 
homozygotes, no significant relationship between reports of supplemental iron use and SF levels 
was found [32]. In an unusual case, a man with hemochromatosis, p.C282Y homozygosity, and 
β-thalassemia minor who ingested ferrous sulfate tablets daily absorbed much iron [33].  
 
The number of units of whole blood donated in a lifetime was not significantly associated with 
iron phenotype classification of the present participants. In a previous study of 124 non-
screening hemochromatosis probands with p.C282Y homozygosity, numbers of units of whole 
blood donated before diagnosis were not significantly related to the numbers of units of 
therapeutic phlebotomy required to achieve iron depletion [34]. In another study, there was no 
significant difference in self-reported initial mean SF levels between non-screening 
hemochromatosis probands with p.C282Y homozygosity who were volunteer blood donors 
before diagnosis and those who were not [35]. In the present study and in previous reports 
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[34,35], the proportions of persons who donated blood before hemochromatosis diagnoses were 
small. 
 
Twelve of the present men reported former or current moderate or heavy daily alcohol 
consumption at the time of enrollment in our original study [16]. They were excluded from the 
original analyses because it was postulated that their alcohol consumption may have modified 
their iron phenotypes [16]. The strong univariable association of p.D519G positivity with 
markedly increased iron stores in the present study is consistent with our original report [16], 
from which the same 12 subjects with moderate or heavy alcohol consumption were excluded. In 
a review of three large studies of patients with classic hemochromatosis or hemochromatosis 
with p.C282Y homozygosity, Fletcher and Powell concluded that it was unlikely that heavy 
alcohol consumption increased either dietary iron intake or iron absorption [36]. In 129x1/SvJ 
mice with wild-type Hfe genotypes, alcohol treatment increased iron absorption significantly, 
whereas heterozygosity or homozygosity for a Hfe knockout abrogated the alcohol-induced iron 
absorption response [37]. It was deduced that either the Hfe knockout causes maximal 
suppression of hepcidin levels or Hfe is a component of a pathway utilized by alcohol to 
decrease hepcidin production and increase iron absorption [37]. Alcohol treatment did not 
enhance the iron absorption of C57BL/6J and AKR/J mice [37].  
 
Alcohol can be hepatotoxic. It was estimated that the daily consumption of 30 g [38,39] or >60 g 
[36,40] of alcohol can worsen iron-related liver injury. In persons with cirrhosis, daily 
consumption of these amounts of alcohol may also increase the risk of hepatocellular carcinoma 
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[36,39]. Persons with hepatic injury due to iron overload associated with hemochromatosis may 
benefit abstaining from consuming alcohol. 
 
Limitations of the present study include the small number of women with markedly increased 
iron stores whose data were available for analysis. Thus, it is unknown whether GNPAT 
p.D519G positivity would be significantly associated with markedly increased iron stores in a 
larger cohort that included more women. The doses and schedules of supplemental iron ingested 
and durations of supplemental iron use by the present participants are unknown. Although 
GNPAT siRNA treatment markedly decreased hepcidin expression in HepG2/C3A cells [16], the 
mechanism(s) by which p.D519G (or a putative linked allele on chromosome 1q) promotes iron 
absorption in white p.C282Y homozygotes [16,17] and in French men with p.C282Y/p.H63D 
and severe iron phenotypes [21] or increases serum iron levels in Taiwanese women without 
p.C282Y [41] has not been reported.  
 
Conclusions 
GNPAT p.D519G is strongly associated with markedly increased iron stores in p.C282Y 
homozygotes after correction for age, iron-related exposure variables, and alcohol consumption. 
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Table 1. Serum ferritin (SF) levels at diagnosis in 56 p.C282Y homozygotes
1 
 
Iron phenotype (n) Median SF, 
pmol/L (µg/L)
 
e
Mean 
SF
2
 [95% confidence 
interval], pmol/L (µg/L) 
Range, 
pmol/L (µg/L) 
Markedly increased iron 
stores (41) 
6265  
(2788) 
6184 [5218, 7256]  
(2752 [2322, 3229]) 
2337-20794 
(1040-9254) 
Normal or mildly elevated 
iron stores (15) 
710  
(316) 
679 [431, 1063]  
(302 [192, 473]) 
148-1849  
(66-823) 
 
1
Criteria for markedly increased iron stores were: SF >2247 pmol/L (>1000 µg/L) at diagnosis 
and either hepatic iron >236 µmol/g dry weight or iron >10 g by induction phlebotomy. Criteria 
for normal or mildly elevated iron stores were: SF <674.1 pmol/L (<300 µg/L) or either age ≥40 
y with iron ≤2.5 g iron by induction phlebotomy or age ≥50 y with ≤3.0 g iron by induction 
phlebotomy. 
 
2
SF values are not normally distributed. Thus, we computed the means of logeSF values and 
corresponding 95% confidence intervals and display the corresponding antilogse. 
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Table 2. Characteristics of 56 HFE p.C282Y homozygotes
1
 
 
Characteristic Markedly increased 
iron stores
2
  
(n = 41) 
Normal or mildly 
elevated iron stores
2
  
(n = 15) 
Value of 
p 
Mean age, y (SD) 54 (10.6) 57 (9.6) 0.57
3 
Male, % (n) 93 (38) 100 (15) 0.56
4
 
Use of iron supplements, % (n) 15 (6/41) 40 (6/15) 0.064
4
 
Mean whole blood units donated 
(SD) 
4.2 (9.61) 4.4 (7.61) 0.71
3
 
Mean erythrocyte units received 
as transfusion (SD) 
0.2 (0.99) 0.2 (0.56) 0.73
3 
Mean estimated daily alcohol 
consumption, g (SD) 
9.8 (17.04) 4.2 (7.77) 0.85
3
 
Diabetes diagnosis, % (n)  12 (5/41) 13 (2/15) 1.00
4
 
Mean BMI, kg/m
2
 (SD) 27.9 (5.54) 28.5 (4.43) 0.63
3
 
Swollen/tender MCP joints, % (n) 56 (23/41) 0 (0/14) 0.0001
4
 
Elevated ALT, % (n)  68 (25/37) 13 (2/15) 0.001
4
 
Elevated AST, % (n)  57 (23/40) 0 (0/15) <0.0001
4
 
Positivity for GNPAT p.D519G, % 
(n)
5
  
59 (24/41) 13 (2/15) 0.003
4
 
 
1
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body 
mass index; MCP, metacarpophalangeal.
 
2
Markedly increased iron stores: SF >2247 pmol/L (>1000 µg/L) at diagnosis and either hepatic 
iron concentration >236 µmol/g dry weight (reference range 0 - 36 µmol/g) or mobilized body 
iron >10 g by induction phlebotomy. Normal or mildly elevated iron stores: SF <674.1 pmol/L 
(<300 µg/L) or either age ≥40 y with ≤2.5 g iron by induction phlebotomy, or age ≥50 y with 
≤3.0 g iron by induction phlebotomy.  
3
Wilcoxon Rank-Sum test. 
4Fisher’s exact test. 
5
Heterozygosity or homozygosity. 
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Table 3. Odds ratios of having markedly increased iron stores
1 
Characteristic Odds 
Ratio 
95% Wald Confidence 
Limits 
AUC p-value 
of 
Wald 
Chi- 
Square 
test 
Age at diagnosis, y 0.97 0.92 1.03 0.55 0.3543 
Use of iron supplements 0.26 0.07 0.99 0.63 0.0483 
Erythrocyte units received as 
transfusion 
1.06 0.52 2.18 0.48 0.8701 
Whole blood units donated  1.00 0.94 1.06 0.53 0.9397 
Average estimated daily alcohol 
consumption, g 
1.04 0.98 1.10 0.54 0.2479 
Positivity for GNPAT p.D519G
2
  9.18 1.83 46.05 0.73 0.0071 
 
1
Results of univariable analyses. Area under the curve for the multivariable logistic regression 
analysis was 0.82.  
2
Heterozygosity or homozygosity.  
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
revision of BCMD_2016_135 - 20 
  
 
 
References 
 
 1.  Saddi R, Feingold J: Idiopathic haemochromatosis: an autosomal recessive disease. Clin 
Genet 1974, 5:234-241. 
 2.  Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, 
Domingo R, Jr., Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, 
Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller 
N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, 
Drayna DT, Risch NJ et al.: A novel MHC class I-like gene is mutated in patients with 
hereditary haemochromatosis. Nat Genet 1996, 13:399-408. 
 3.  Edwards CQ, Barton J.C.: Hemochromatosis. In Wintrobe's Clinical Hematology. 13th 
ed. Edited by Edited by Greer JP, Arber DA, Glader B, List AF, Means Jr. RT, 
Paraskevas F, Rodgers GM. Philadelphia: Wolters Kluwer/Lippincott Williams & 
Wilkins; 2014:662-681. 
 4.  Nemeth E, Ganz T: The role of hepcidin in iron metabolism. Acta Haematol 2009, 
122:78-86. 
 5.  Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren 
CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English 
DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM: Iron-overload-related disease in 
HFE hereditary hemochromatosis. N Engl J Med 2008, 358:221-230. 
 6.  McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton 
RT, Harris EL, Speechley MR, Sholinsky P, Dawkins FW, Snively BM, Vogt TM, 
Eckfeldt JH: Clinical manifestations of hemochromatosis in HFE C282Y homozygotes 
identified by screening. Can J Gastroenterol 2008, 22:923-930. 
 7.  Åsberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelonning K, Fjosne U, Halvorsen 
TB, Smethurst HB, Sagen E, Bjerve KS: Screening for hemochromatosis: high 
prevalence and low morbidity in an unselected population of 65,238 persons. Scand J 
Gastroenterol 2001, 36:1108-1115. 
 8.  Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T: Penetrance of 845G->A (C282Y) 
HFE hereditary haemochromatosis mutation in the USA. Lancet 2002, 359:211-218. 
 9.  Beutler E: Penetrance of haemochromatosis. Gut 2003, 52:610-611. 
 10.  Adams PC, Deugnier Y, Moirand R, Brissot P: The relationship between iron overload, 
clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 
1997, 25:162-166. 
 11.  Bothwell TH, Charlton RW, Cook JD, Finch CD: Iron Metabolism in Man. Oxford: 
Blackwell Scientific Publications; 1979. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
revision of BCMD_2016_135 - 21 
  
 
 12.  Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y: Clinical features of genetic 
hemochromatosis in women compared with men. Ann Intern Med 1997, 127:105-110. 
 13.  Barton JC, Edwards CQ, Acton RT: HFE gene: Structure, function, mutations, and 
associated iron abnormalities. Gene 2015, 574:179-192. 
 14.  McLaren CE, Barton JC, Eckfeldt JH, McLaren GD, Acton RT, Adams PC, Henkin LF, 
Gordeuk VR, Vulpe CD, Harris EL, Harrison BW, Reiss JA, Snively BM: Heritability of 
serum iron measures in the Hemochromatosis and Iron Overload Screening (HEIRS) 
family study. Am J Hematol 2010, 85:101-105. 
 15.  Thai TP, Rodemer C, Jauch A, Hunziker A, Moser A, Gorgas K, Just WW: Impaired 
membrane traffic in defective ether lipid biosynthesis. Hum Mol Genet 2001, 10:127-136. 
 16.  McLaren CE, Emond MJ, Subramaniam VN, Phatak PD, Barton JC, Adams PC, Goh JB, 
McDonald CJ, Powell LW, Gurrin LC, Allen KJ, Nickerson DA, Louie T, Ramm GA, 
Anderson GJ, McLaren GD: Exome sequencing in HFE C282Y homozygous men with 
extreme phenotypes identifies a GNPAT variant associated with severe iron overload. 
Hepatology 2015, 62:429-439. 
 17.  Besson-Fournier C, Martinez M, Vinel JP, Aguilar-Martinez P, Coppin H, Roth MP: 
Further support for the association of GNPAT variant rs11558492 with severe iron 
overload in hemochromatosis. Hepatology 2015. 
 18.  McLaren CE, Barton JC, Subramaniam VN, Ramm GA, Phatak PD, Emond MJ, Gurrin 
LC, Adams PC, Powell LW, Anderson GJ, McLaren GD: Reply. Hepatology 2016. 
 19.  Adams PC, Barton JC: How I treat hemochromatosis. Blood 2010, 116:317-325. 
 20.  Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, Subramaniam 
VN, Hewett DG, Searle JW, Fletcher LM, Crawford DH, Rodgers H, Allen KJ, 
Cavanaugh JA, Bassett ML: Screening for hemochromatosis in asymptomatic subjects 
with or without a family history. Arch Intern Med 2006, 166:294-301. 
 21.  Tachon G, Roth M-P, Calcoen F, Besson-Fournier C, Bismuth M, Aguilar-Martinez P: 
Phenotypic variability in genetic hemochromatosis: study of five SNPs in a cohort of 342 
compound heterozygotes for the HFE Cys282Tyr/His63Asp mutations. Blood 2015, 
126:3361. 
 22.  Bardou-Jacquet E, de Tayrac M., Mosser J, Deugnier Y: GNPAT variant associated with 
severe iron overload in HFE hemochromatosis. Hepatology 2015, 62:1917-1918. 
 23.  Levstik A, Stuart A, Adams PC: GNPAT variant (D519G) is not associated with an 
elevated serum ferritin or iron removed by phlebotomy in patients referred for C282Y-
linked hemochromatosis. Ann Hepatol 2016, 15:907-910. 
 24.  Ryan E, Russell J, Ryan JD, Crowe J, Stewart S: GNPAT variant is not associated with 
severe iron overload in Irish C282Y homozygotes. Hepatology 2015. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
revision of BCMD_2016_135 - 22 
  
 
 25.  Lipschitz DA, Cook JD, Finch CA: A clinical evaluation of serum ferritin as an index of 
iron stores. N Engl J Med 1974, 290:1213-1216. 
 26.  Beutler E, Felitti V, Ho NJ, Gelbart T: Relationship of body iron stores to levels of serum 
ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in 
patients with iron storage disease. Acta Haematol 2002, 107:145-149. 
 27.  Valenti L, Fracanzani AL, Rossi V, Rampini C, Pulixi E, Varenna M, Fargion S, 
Sinigaglia L: The hand arthropathy of hereditary hemochromatosis is strongly associated 
with iron overload. J Rheumatol 2008, 35:153-158. 
 28.  Lin E, Adams PC: Biochemical liver profile in hemochromatosis. A survey of 100 
patients. J Clin Gastroenterol 1991, 13:316-320. 
 29.  Brissot P, Guyader D, Loreal O, Laine F, Guillygomarc'h A, Moirand R, Deugnier Y: 
Clinical aspects of hemochromatosis. Transfus Sci 2000, 23:193-200. 
 30.  Bassett ML, Halliday JW, Powell LW: Value of hepatic iron measurements in early 
hemochromatosis and determination of the critical iron level associated with fibrosis. 
Hepatology 1986, 6:24-29. 
 31.  McDonnell SM, Grindon AJ, Preston BL, Barton JC, Edwards CQ, Adams PC: A survey 
of phlebotomy among persons with hemochromatosis. Transfusion 1999, 39:651-656. 
 32.  Gordeuk VR, Lovato L, Barton J, Vitolins M, McLaren G, Acton R, McLaren C, Harris 
E, Speechley M, Eckfeldt JH, Diaz S, Sholinsky P, Adams P: Dietary iron intake and 
serum ferritin concentration in 213 patients homozygous for the HFE C282Y 
hemochromatosis mutation. Can J Gastroenterol 2012, 26:345-349. 
 33.  Barton JC, Lee PL, West C, Bottomley SS: Iron overload and prolonged ingestion of iron 
supplements: clinical features and mutation analysis of hemochromatosis-associated 
genes in four cases. Am J Hematol 2006, 81:760-767. 
 34.  Barton JC, Preston BL, McDonnell SM, Rothenberg BE: Severity of iron overload in 
hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion 2001, 
41:123-129. 
 35.  Power TE, Adams PC: Hemochromatosis patients as voluntary blood donors. Can J 
Gastroenterol 2004, 18:393-396. 
 36.  Fletcher LM, Powell LW: Hemochromatosis and alcoholic liver disease. Alcohol 2003, 
30:131-136. 
 37.  Flanagan JM, Peng H, Beutler E: Effects of alcohol consumption on iron metabolism in 
mice with hemochromatosis mutations. Alcohol Clin Exp Res 2007, 31:138-143. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
revision of BCMD_2016_135 - 23 
  
 
 38.  LeSage GD, Baldus WP, Fairbanks VF, Baggenstoss AH, McCall JT, Moore SB, Taswell 
HF, Gordon H: Hemochromatosis: genetic or alcohol-induced? Gastroenterology 1983, 
84:1471-1477. 
 39.  Deugnier YM, Guyader D, Crantock L, Lopez JM, Turlin B, Yaouanq J, Jouanolle H, 
Campion JP, Launois B, Halliday JW, .: Primary liver cancer in genetic 
hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. 
Gastroenterology 1993, 104:228-234. 
 40.  Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH: Excess alcohol greatly 
increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 
2002, 122:281-289. 
 41.  Hsiao SC, Lee CT, Pei SN: GNPAT variant is associated with iron phenotype in healthy 
Taiwanese women: A population without the HFE C282Y mutation. Hepatology 2016. 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
revision of BCMD_2016_135 - 24 
  
 
Figure Caption 
Fig.1. Schema of participant selection. Asterisk refers to McLaren CE et al. Hepatology 2015; 
62: 429-439 [16]. Exome sequencing of the DNA of the nine additional participants (6 men, 3 
women) was performed after our report of the initial 49 men [16].  
  
   
 
49 men with HFE p.C282Y homozygosity  
underwent exome sequencing*  
PARTICIPANT SELECTION 
PRESENT COHORT: 56 PARTICIPANTS 
 38 men, 3 women with markedly 
increased iron stores 
 15 men with normal/mildly  increased 
iron stores 
9 other p.C282Y homozygotes  
(6 men, 3 women) underwent 
exome sequencing 
35 men with p.C282Y homozygosity 
reported* 
 and 
12 other men with p.C282Y 
homozygosity and moderate/heavy 
alcohol consumption previously 
excluded* 
2 men excluded* 
 1 suboptimal 
DNA quality  
 1 p.C282Y 
heterozygote 
